SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Gennaro Pagano, Echo E Tan, Janelle M. Haider, Alyssa Bautista, Michele Tagliati, Constipation is reduced by beta-blockers and increased by dopaminergic medications in Parkinson's disease, Parkinsonism & Related Disorders, 2015, 21, 2, 120

    CrossRef

  2. 2
    Fabrizio Stocchi, Laura Vacca, Fabiana G Radicati, How to optimize the treatment of early stage Parkinson’s disease, Translational Neurodegeneration, 2015, 4, 1, 4

    CrossRef

  3. 3
    Thien Thien Lim, Benzi M. Kluger, Ramon L. Rodriguez, Irene A. Malaty, Rafael Palacio, Oluwadamilola O. Ojo, Shnehal Patel, Yogesh Gujrati, Benjamin Nutter, Camille Swartz, Carol Hennessy, Hubert H. Fernandez, Rasagiline for the symptomatic treatment of fatigue in Parkinson's disease, Movement Disorders, 2015, 30, 13
  4. 4
    A. Alonso Cánovas, R. Luquin Piudo, P. García Ruiz-Espiga, J.A. Burguera, V. Campos Arillo, A. Castro, G. Linazasoro, J. López del Val, L. Vela, J.C. Martínez Castrillo, Agonistas dopaminérgicos en la enfermedad de Parkinson, Neurología, 2014, 29, 4, 230

    CrossRef

  5. 5
    A. Alonso Cánovas, R. Luquin Piudo, P. García Ruiz-Espiga, J.A. Burguera, V. Campos Arillo, A. Castro, G. Linazasoro, J. López Del Val, L. Vela, J.C. Martínez Castrillo, Dopaminergic agonists in Parkinson's disease, Neurología (English Edition), 2014, 29, 4, 230

    CrossRef

  6. 6
    Matthias Löhle, Carl-Johan Ramberg, Heinz Reichmann, Anthony H. V. Schapira, Early Versus Delayed Initiation of Pharmacotherapy in Parkinson’s Disease, Drugs, 2014, 74, 6, 645

    CrossRef

  7. 7
    Robert A. Hauser, Mark Forrest Gordon, Yoshikuni Mizuno, Werner Poewe, Paolo Barone, Anthony H. Schapira, Olivier Rascol, Catherine Debieuvre, Mandy Fräßdorf, Minimal Clinically Important Difference in Parkinson’s Disease as Assessed in Pivotal Trials of Pramipexole Extended Release, Parkinson's Disease, 2014, 2014, 1

    CrossRef

  8. 8
    James E. Frampton, Pramipexole Extended-Release: A Review of Its Use in Patients with Parkinson’s Disease, Drugs, 2014, 74, 18, 2175

    CrossRef

  9. 9
    Rajesh Pahwa, Kelly E. Lyons, Treatment of early Parkinsonʼs disease, Current Opinion in Neurology, 2014, 27, 4, 442

    CrossRef

  10. 10
    Qing Lv, Baorong Zhang, Application of the concept of continuous dopaminergic stimulation for the management of Parkinson’s disease, Neuroscience Bulletin, 2013, 29, 5, 661

    CrossRef

  11. 11
    Brenton A Wright, Cheryl H Waters, Continuous dopaminergic delivery to minimize motor complications in Parkinson’s disease, Expert Review of Neurotherapeutics, 2013, 13, 6, 719

    CrossRef

  12. 12
    Scott Kaplan, Daniel Tarsy, Initial Treatment of Parkinson’s Disease: An Update, Current Treatment Options in Neurology, 2013, 15, 4, 377

    CrossRef

  13. 13
    Marjolein A van der Marck, Marten Munneke, Wim Mulleners, Edo M Hoogerwaard, George F Borm, Sebastiaan Overeem, Bastiaan R Bloem, Integrated multidisciplinary care in Parkinson's disease: a non-randomised, controlled trial (IMPACT), The Lancet Neurology, 2013, 12, 10, 947

    CrossRef

  14. 14
    K. Ray Chaudhuri, Alexandra Rizos, Kapil D. Sethi, Motor and nonmotor complications in Parkinson’s disease: an argument for continuous drug delivery?, Journal of Neural Transmission, 2013, 120, 9, 1305

    CrossRef

  15. 15
    A. H. V. Schapira, P. Barone, R. A. Hauser, Y. Mizuno, O. Rascol, M. Busse, C. Debieuvre, M. Fraessdorf, W. Poewe, Patient-reported convenience of once-daily versus three-times-daily dosing during long-term studies of pramipexole in early and advanced Parkinson’s disease, European Journal of Neurology, 2013, 20, 1
  16. 16
    Carlos Zúñiga-Ramírez, Federico Micheli, Preladenant: an adenosine A2Areceptor antagonist for Parkinson’s disease, Future Neurology, 2013, 8, 6, 639

    CrossRef

  17. 17
    Santiago Perez-Lloret, María Verónica Rey, Pietro Lucca Ratti, Olivier Rascol, Rotigotine transdermal patch for the treatment of Parkinson’s Disease, Fundamental & Clinical Pharmacology, 2013, 27, 1
  18. You have free access to this content18
    J. J. Ferreira, R. Katzenschlager, B. R. Bloem, U. Bonuccelli, D. Burn, G. Deuschl, E. Dietrichs, G. Fabbrini, A. Friedman, P. Kanovsky, V. Kostic, A. Nieuwboer, P. Odin, W. Poewe, O. Rascol, C. Sampaio, M. Schüpbach, E. Tolosa, C. Trenkwalder, A. Schapira, A. Berardelli, W. H. Oertel, Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease, European Journal of Neurology, 2013, 20, 1
  19. 19
    Valerie Suski, Mark Stacy, Handbook of Parkinson’s Disease, 2013,

    CrossRef

  20. 20
    Valerie Suski, Mark Stacy, Handbook of Parkinson's Disease, Fifth Edition, 2013,

    CrossRef

  21. 21
    Juliana Dushanova, Diagnostics, rehabilitation and models of Parkinson’s disease, Health, 2012, 04, 11, 1200

    CrossRef

  22. 22
    John C. P. Piedad, Andrea E. Cavanna, Dyskinesias and Treatment with Pramipexole in Patients with Parkinson's Disease, Parkinson's Disease, 2012, 2012, 1

    CrossRef

  23. 23
    O. Gershanik, P. Jenner, Moving from continuous dopaminergic stimulation to continuous drug delivery in the treatment of Parkinson’s disease, European Journal of Neurology, 2012, 19, 12
  24. 24
    A. H. V. Schapira, E. K. Tan, Optimizing treatment for Parkinson's disease, European Journal of Neurology, 2012, 19, 12
  25. 25
    José-Rubén García-Montes, Alejandra Boronat-García, René Drucker-Colín, Pharmacological strategies for Parkinson’s disease, Health, 2012, 04, 11, 1153

    CrossRef

  26. 26
    Joseph Jankovic, Werner Poewe, Therapies in Parkinsonʼs disease, Current Opinion in Neurology, 2012, 25, 4, 433

    CrossRef

  27. 27
    Fabrizio Stocchi, Continuous dopaminergic stimulation and novel formulations of dopamine agonists, Journal of Neurology, 2011, 258, S2, 316

    CrossRef

  28. 28
    O. Rascol, Drugs and drug delivery in PD: optimizing control of symptoms with pramipexole prolonged-release, European Journal of Neurology, 2011, 18,
  29. 29
    Olivier Rascol, Andres Lozano, Matthew Stern, Werner Poewe, Milestones in Parkinson's disease therapeutics, Movement Disorders, 2011, 26, 6
  30. 30
    Eva-Maria Hametner, Klaus Seppi, Werner Poewe, Pramipexole extended release in Parkinson’s disease, Expert Review of Neurotherapeutics, 2011, 11, 9, 1229

    CrossRef

  31. 31
    Santiago Perez-Lloret, María Verónica Rey, Luca Ratti, Olivier Rascol, Pramipexole for the treatment of early Parkinson’s disease, Expert Review of Neurotherapeutics, 2011, 11, 7, 925

    CrossRef

  32. 32
    Akihiko Morita, Yasuyuki Okuma, Satoshi Kamei, Fumihito Yoshii, Toshimasa Yamamoto, Shiori Hashimoto, Hiroya Utsumi, Taku Hatano, Nobutaka Hattori, Miyuki Matsumura, Kazushi Takahashi, Shigeru Nogawa, Yuka Watanabe, Tomoyuki Miyamoto, Masayuki Miyamoto, Koichi Hirata, Pramipexole Reduces the Prevalence of Fatigue in Patients with Parkinson's Disease, Internal Medicine, 2011, 50, 19, 2163

    CrossRef

  33. 33
    Susan H. Fox, Regina Katzenschlager, Shen-Yang Lim, Bernard Ravina, Klaus Seppi, Miguel Coelho, Werner Poewe, Olivier Rascol, Christopher G. Goetz, Cristina Sampaio, The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease, Movement Disorders, 2011, 26, S3
  34. 34
    Nicholas D. Child, Bryan T. Klassen, Evidence-based treatment of Parkinson's disease,
  35. 35
    Roy G Elbers, John Verhoef, Erwin EH van Wegen, Henk W Berendse, Gert Kwakkel, Interventions for fatigue in Parkinson's disease, The Cochrane Library,